NextFin News - Granules India is overhauling its manufacturing oversight and accelerating the digitisation of its compliance records following a stern warning from the U.S. Food and Drug Administration (FDA) regarding systemic quality control failures. The Hyderabad-based drugmaker, which controls approximately 30% of the global paracetamol market, is under intense pressure to remediate issues ranging from data integrity to physical facility maintenance at its Gagillapur facility.
The escalation follows a February 2025 warning letter that detailed alarming lapses, including the discovery of bird droppings and feathers near air purification units and the recovery of 15 bags of shredded manufacturing records. While the company initially received a "Voluntary Action Indicated" (VAI) classification for some inspections earlier this year, the persistent nature of the FDA’s concerns has forced a more radical shift in corporate strategy. K.V.S. Ram Rao, the Joint Managing Director and CEO of Granules India, stated in an interview with Reuters on Thursday that the firm is now implementing a "zero-tolerance" digital framework to eliminate the possibility of manual record tampering.
Rao, a veteran of the Indian pharmaceutical sector with three decades of experience at firms including Dr. Reddy’s and PI Industries, has historically championed operational excellence. However, his current task is one of damage control. The FDA’s warning letter specifically noted that Granules failed to maintain buildings in a good state of repair and lacked robust programs to ensure the performance of essential manufacturing equipment. The agency’s discovery of "too numerous to count" microbial contamination in HEPA filter ducts suggested that previous remediation efforts were largely superficial.
The move toward total digitisation is a direct response to the "data integrity" crisis that has long plagued the Indian generic drug industry. By removing paper-based logs, Granules aims to create an immutable audit trail that satisfies U.S. inspectors. This shift is not merely a regulatory necessity but a survival tactic in an increasingly competitive landscape. Indian API (Active Pharmaceutical Ingredient) makers are currently squeezed between falling prices in Western markets and the strategic need for global drugmakers to diversify supply chains away from China.
Market analysts remain cautious about the speed of this turnaround. While Granules reported a 28% jump in third-quarter profit earlier this year—buoyed by strong demand in North America—the cost of these new oversight measures could weigh on margins. Some sell-side researchers have noted that while Granules is a dominant player in high-volume generics, its transition into complex therapeutics and CDMO (Contract Development and Manufacturing Organization) services through acquisitions like Senn Chemicals will be hampered if the FDA does not lift its current warnings.
The broader Indian pharmaceutical sector is watching Granules closely as a bellwether for regulatory maturity. The company’s failure to address a Form 483 in late 2024, which led to the current warning letter, serves as a reminder that the FDA is no longer accepting "procedural misunderstandings" as a valid excuse for compliance gaps. For Granules, the path forward involves a costly race to automate quality control before the next unannounced inspection determines the fate of its export pipeline.
Explore more exclusive insights at nextfin.ai.
